Protocol Single compound
TB-500
Thymosin Beta-4 fragment
Synthetic fragment of thymosin β-4 researched for cell migration, angiogenesis and soft-tissue recovery.
Compare side by side →Compared with:BPC-157 vs TB-500
Protocol card · research reference
- Starting dose
- 2 mg
- Studied range
- 2–5 mg per week
- Frequency
- 2× weekly (loading), then weekly
- Route
- Subcutaneous
- Cycle
- 4–6 week loading, then maintenance
Titration schedule
- 01Weeks 1–42–2.5 mg, twice weekly
- 02Weeks 5+2 mg, once weekly
Reconstitution reference
Storage: Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.
TB-500
2× weekly (loading), then weekly · units to draw on a U-100 syringe for a 2 mg dose.
| Vial | BAC water | mg/mL | Draw | Doses |
|---|---|---|---|---|
| 5 mg | 1 mL | 5 | 40 u | 2 |
| 5 mg | 2 mL | 2.5 | 80 u | 2 |
| 5 mg | 3 mL | 1.67 | 120 u | 2 |
| 10 mg | 1 mL | 10 | 20 u | 5 |
| 10 mg | 2 mL | 5 | 40 u | 5 |
| 10 mg | 3 mL | 3.33 | 60 u | 5 |
Calculate your vial
Draw to
—units
= — mL on a U-100 syringe
- Concentration
- —
- Per unit
- —
- Doses / vial
- —
Research dossier · published literature summary
01
Mechanism of action
TB-500 is a synthetic peptide based on the active region of thymosin β4, a 43-amino-acid protein that binds G-actin and is involved in cell migration. Thymosin β4 research links it to endothelial and keratinocyte migration, angiogenesis and wound repair.
02
Observed research endpoints
- In a rat full-thickness wound model, thymosin β4 increased re-epithelialisation by 42% at day 4 and up to 61% at day 7 vs saline.
- Treated wounds contracted at least 11% more by day 7, with more collagen deposition and new blood vessels.
- Keratinocyte migration rose 2–3-fold in cell-culture assays.
03
Regulatory & safety context
- Most evidence is on full-length thymosin β4; data on the TB-500 fragment itself is limited.
- Not approved for human use; listed as prohibited by the World Anti-Doping Agency.
04
Citations
- Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364–368.1999-09Animal + in vitro studyRead paper ↗
- Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37–51.2012Narrative reviewRead paper ↗
Keep exploring
Related compounds
Found in these stacks & blends
Head-to-head articles
Where researchers source it
Listings are provided for reference — always verify the latest third-party COA before purchasing.
Medvinci Research
See siteFeatured supplier · third-party tested, COA published per batch
Supplier B
TBDPlaceholder — details coming soon
Supplier C
TBDPlaceholder — details coming soon